Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Not applicable Interventional

Cognitive Augmentation, Remediation, and TDCS for Schizophrenia

ClinicalTrials.gov ID: NCT07940712

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07940712. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cognitive Augmentation, Remediation, and TDCS for Schizophrenia (CARTS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Schizophrenia-spectrum disorders (SSDs; schizophrenia, schizoaffective disorder, etc.) are among the most disabling and costly conditions globally. Most SSD medications treat symptoms like hallucinations and delusions, but cognitive symptoms, or problems with thinking, memory, and problem solving, remain untreated by medication. Other developing treatments for these symptoms include noninvasive stimulation of cognitive brain regions and behavioral therapies involving mental skill-building activities. While both of these treatments appear to improve cognitive symptoms, effects are inconsistent depending on specific details of the trial. Growing evidence suggests that using these therapies together could lead to larger, clinically meaningful effects. Still, prior combined therapy trials use simplified versions of the behavioral therapy, omitting the guidance of a therapist to engage and challenge the participant. These previous trials show some evidence for beneficial effects, particularly in working memory, but the omission of a therapist could limit effects. This study will be the first to test if using a comprehensive, therapist-guided behavioral therapy can amplify the effects of noninvasive brain stimulation (NIBS) to reduce cognitive symptoms and change brain activity in SSDs. We will conduct a small pilot study to gather preliminary evidence for this combined therapy using 10 participants split into 2 groups. One group will receive NIBS and comprehensive cognitive therapy (NIBS+) while the other receives NIBS and performs quizzes without the guidance of a therapist (NIBS-). Participants will receive therapies for 10 days over 2 weeks with 2 hours of therapy per day. We will compare interventions through the following aims. Aim 1 will examine changes in brain connections after NIBS+ and NIBS-. We will collect data from electrical brain recordings (electroencephalography/EEG) before and after interventions. We expect that connections between cognitive brain regions will be most strengthened by NIBS+ compared to NIBS-. Aim 2 will investigate what kind of cognitive symptoms are affected by NIBS+ and NIBS-. We will perform cognitive tests before and after the interventions. We expect that all cognitive symptoms (memory, motor speed, language skills, attention, processing speed, and planning abilities) will be most improved by NIBS+ compared to NIBS-, but that the largest improvements will be in short-term, active memory skills ("working memory"). We will also investigate if there is a relationship between the changes in brain connections and cognitive improvements. This preliminary study will provide early evidence that the effects of noninvasive brain stimulation can be strengthened by a structured, therapist-guided behavioral therapy for cognitive symptoms. This will support the development of a new, combined therapy for untreated cognitive symptoms in schizophrenia-spectrum disorders. We will use findings of this study to support a trial proposal to the National Institute of Mental Health to test this therapy in a larger group of individuals.

Study identification

NCT ID
NCT07940712
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Not applicable
Enrollment
10 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 40 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2026 (Estimated)
Primary completion
Nov 2027 (Estimated)
Completion
Nov 2027 (Estimated)
Last update posted
Nov 17, 2026

2026 – 2027

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07940712, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.